UroGen Pharma (URGN) Financials

$10.75 +0.15 (+1.42%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$10.76 +0.01 (+0.09%)

As of 04/15/2025 04:05 PM Eastern

Annual Income Statements for UroGen Pharma

This table shows UroGen Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-110	-102	-127
Consolidated Net Income / (Loss)	-110	-102	-127
Net Income / (Loss) Continuing Operations	-110	-102	-127
Total Pre-Tax Income	-108	-98	-124
Total Operating Income	-79	-66	-97
Total Gross Profit	57	73	82
Total Revenue	64	83	90
Operating Revenue	64	83	90
Total Cost of Revenue	7.65	9.36	8.88
Operating Cost of Revenue	7.65	9.36	8.88
Total Operating Expenses	136	139	178
Selling, General & Admin Expense	83	93	121
Research & Development Expense	53	46	57
Total Other Income / (Expense), net	-29	-33	-27
Interest Expense	8.44	15	13
Interest & Investment Income	1.01	3.48	8.67
Other Income / (Expense), net	-22	-22	-23
Income Tax Expense	1.76	3.92	2.83
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.08	-0.12	-0.04
Basic Earnings per Share	($4.81)	($3.55)	($2.96)
Weighted Average Basic Shares Outstanding	22.81M	28.83M	42.88M
Weighted Average Diluted Shares Outstanding	23.44M	34.12M	46.09M
Weighted Average Basic & Diluted Shares Outstanding	23.44M	34.12M	46.09M

This table shows UroGen Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-26	-29	-30	-24	-22	-26	-32	-33	-23	-38
Consolidated Net Income / (Loss)	-26	-29	-30	-24	-22	-26	-32	-33	-24	-38
Net Income / (Loss) Continuing Operations	-26	-29	-30	-24	-22	-26	-32	-33	-24	-38
Total Pre-Tax Income	-25	-28	-30	-24	-22	-22	-32	-33	-24	-35
Total Operating Income	-18	-20	-22	-15	-14	-15	-26	-26	-18	-28
Total Gross Profit	14	16	15	19	18	21	17	20	23	22
Total Revenue	16	18	17	21	21	24	19	22	25	25
Operating Revenue	16	18	17	21	21	24	19	22	25	25
Total Cost of Revenue	2.02	2.26	2.27	2.44	2.37	2.29	1.73	2.23	2.45	2.47
Operating Cost of Revenue	2.02	2.26	2.27	2.44	2.37	2.29	1.73	2.23	2.45	2.47
Total Operating Expenses	32	36	37	34	32	36	43	45	40	50
Selling, General & Admin Expense	19	22	24	22	22	25	27	30	29	35
Research & Development Expense	13	14	12	12	10	11	15	15	11	15
Total Other Income / (Expense), net	-7.04	-7.90	-8.15	-8.70	-8.39	-7.55	-6.49	-7.53	-6.04	-7.21
Interest Expense	2.69	3.22	3.55	3.76	3.82	3.59	2.45	3.46	2.72	3.89
Interest & Investment Income	0.48	0.41	0.63	0.41	0.91	1.54	1.62	1.71	2.60	2.75
Other Income / (Expense), net	-4.82	-5.08	-5.22	-5.34	-5.48	-5.51	-5.66	-5.77	-5.92	-6.06
Income Tax Expense	0.71	0.69	0.02	0.05	-0.01	3.85	0.05	0.04	0.09	2.65
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.10	-	-0.06	0.11	-0.02	-0.15	0.05	-0.01	-0.27	0.18
Basic Earnings per Share	($1.13)	($1.25)	($1.30)	($1.03)	($0.68)	($0.54)	($0.97)	($0.91)	($0.55)	($0.53)
Weighted Average Basic Shares Outstanding	22.80M	22.81M	23.28M	23.46M	32.30M	28.83M	33.38M	36.82M	43.10M	42.88M
Weighted Average Diluted Shares Outstanding	23.09M	23.44M	23.45M	30.28M	30.87M	34.12M	36.13M	42.11M	42.20M	46.09M
Weighted Average Basic & Diluted Shares Outstanding	23.09M	23.44M	23.45M	30.28M	30.87M	34.12M	36.13M	42.11M	42.20M	46.09M

This table details how cash moves in and out of UroGen Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	11	40	77
Net Cash From Operating Activities	-88	-76	-97
Net Cash From Continuing Operating Activities	-88	-76	-97
Net Income / (Loss) Continuing Operations	-110	-102	-127
Consolidated Net Income / (Loss)	-110	-102	-127
Depreciation Expense	0.92	0.80	0.33
Amortization Expense	2.15	-0.02	-3.34
Non-Cash Adjustments To Reconcile Net Income	24	21	28
Changes in Operating Assets and Liabilities, net	-5.18	4.32	4.88
Net Cash From Investing Activities	1.06	-0.95	-21
Net Cash From Continuing Investing Activities	1.06	-0.95	-21
Purchase of Property, Plant & Equipment	-0.25	-0.19	-0.30
Purchase of Investments	-63	-50	-128
Sale and/or Maturity of Investments	64	49	108
Net Cash From Financing Activities	97	117	195
Net Cash From Continuing Financing Activities	97	117	195
Issuance of Debt	96	0.00	24
Issuance of Common Equity	0.00	116	170
Other Financing Activities, net	1.51	0.87	0.32

This table details how cash moves in and out of UroGen Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-52	27	-19	-16	99	-24	36	89	-95	47
Net Cash From Operating Activities	-18	-22	-26	-20	-17	-13	-32	-24	-28	-14
Net Cash From Continuing Operating Activities	-18	-22	-26	-20	-17	-13	-32	-24	-28	-14
Net Income / (Loss) Continuing Operations	-26	-29	-30	-24	-22	-26	-32	-33	-24	-38
Consolidated Net Income / (Loss)	-26	-29	-30	-24	-22	-26	-32	-33	-24	-38
Depreciation Expense	0.24	0.24	0.22	0.21	0.19	0.19	0.12	0.07	0.07	0.07
Amortization Expense	0.61	0.49	0.27	0.27	0.49	-1.05	-0.92	0.12	-1.47	-1.07
Non-Cash Adjustments To Reconcile Net Income	5.17	5.34	5.16	4.83	4.69	6.17	5.11	7.20	6.56	9.37
Changes in Operating Assets and Liabilities, net	2.20	1.05	-1.24	-1.44	-0.79	7.80	-3.76	2.27	-9.15	16
Net Cash From Investing Activities	-35	23	6.27	3.72	0.40	-11	14	12	-107	61
Net Cash From Continuing Investing Activities	-35	23	6.27	3.72	0.40	-11	14	12	-107	61
Purchase of Property, Plant & Equipment	-0.15	-0.01	-0.02	-0.02	-0.10	-0.06	0.00	-0.08	-0.10	-0.12
Purchase of Investments	-63	-	-24	-	-11	-15	0.00	-	-119	-9.23
Sale and/or Maturity of Investments	28	23	30	3.74	11	3.54	14	12	12	70
Net Cash From Financing Activities	1.10	25	0.67	0.14	116	0.04	55	100	40	0.07
Net Cash From Continuing Financing Activities	1.10	25	0.67	0.14	116	0.04	55	100	40	0.07
Other Financing Activities, net	1.12	0.38	0.67	0.14	0.02	0.04	0.00	0.14	0.12	0.07

This table presents UroGen Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	136	178	286
Total Current Assets	129	169	276
Cash & Equivalents	55	95	172
Restricted Cash	0.81	0.82	1.08
Short-Term Investments	45	42	65
Accounts Receivable	13	15	20
Inventories, net	4.33	5.67	9.23
Prepaid Expenses	11	10	8.85
Plant, Property, & Equipment, net	1.30	0.69	0.66
Total Noncurrent Assets	5.42	8.44	8.92
Long-Term Investments	0.22	4.73	5.20
Other Noncurrent Operating Assets	5.19	3.71	3.72
Total Liabilities & Shareholders' Equity	136	178	286
Total Liabilities	225	244	295
Total Current Liabilities	24	31	46
Accounts Payable	12	17	27
Current Employee Benefit Liabilities	8.26	11	11
Other Current Liabilities	3.28	3.86	7.95
Total Noncurrent Liabilities	201	212	249
Long-Term Debt	98	99	122
Capital Lease Obligations	-	0.84	1.65
Noncurrent Deferred & Payable Income Tax Liabilities	3.02	3.19	3.79
Other Noncurrent Operating Liabilities	101	110	121
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-89	-65	-8.80
Total Preferred & Common Equity	-89	-65	-8.80
Total Common Equity	-89	-65	-8.80
Common Stock	488	614	797
Retained Earnings	-577	-679	-806
Accumulated Other Comprehensive Income / (Loss)	-0.11	0.01	0.06

This table presents UroGen Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	128	113	95	194	201	282	302
Total Current Assets	122	96	81	182	197	279	295
Cash & Equivalents	29	37	20	119	131	220	125
Restricted Cash	0.81	0.81	0.82	0.82	0.82	0.83	1.07
Short-Term Investments	67	29	27	28	33	21	125
Accounts Receivable	9.43	12	16	13	14	17	23
Inventories, net	4.86	5.47	4.99	5.00	7.24	7.44	7.59
Prepaid Expenses	11	12	13	16	10	12	14
Plant, Property, & Equipment, net	1.52	1.10	0.91	0.82	0.57	0.58	0.61
Total Noncurrent Assets	5.36	16	13	11	3.25	2.30	6.24
Long-Term Investments	0.22	10	8.19	6.73	0.71	0.38	4.82
Other Noncurrent Operating Assets	5.14	5.49	4.92	3.96	2.54	1.92	1.42
Total Liabilities & Shareholders' Equity	128	113	95	194	201	282	302
Total Liabilities	192	230	234	236	241	252	276
Total Current Liabilities	19	25	27	26	26	34	33
Accounts Payable	9.36	17	16	14	18	24	20
Current Employee Benefit Liabilities	6.63	4.92	6.72	8.15	4.99	6.85	9.03
Other Current Liabilities	3.02	3.19	3.64	3.55	3.20	3.62	4.07
Total Noncurrent Liabilities	173	204	207	210	214	217	244
Long-Term Debt	72	98	98	99	98	98	122
Noncurrent Deferred & Payable Income Tax Liabilities	2.84	3.02	3.02	3.02	3.19	3.19	3.19
Other Noncurrent Operating Liabilities	98	103	106	108	114	116	119
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	-	0.00
Total Equity & Noncontrolling Interests	-63	-117	-138	-42	-40	30	26
Total Preferred & Common Equity	-63	-117	-138	-42	-40	30	26
Total Common Equity	-63	-117	-138	-42	-40	30	26
Common Stock	485	491	493	611	672	775	794
Retained Earnings	-548	-607	-631	-653	-712	-745	-769
Accumulated Other Comprehensive Income / (Loss)	-0.16	-0.05	-0.15	-0.13	-0.04	-0.03	0.24

This table displays calculated financial ratios and metrics derived from UroGen Pharma's official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	33.96%	28.52%	9.29%
EBITDA Growth	9.14%	11.51%	-42.75%
EBIT Growth	8.20%	13.43%	-38.01%
NOPAT Growth	14.36%	17.09%	-47.68%
Net Income Growth	0.94%	6.87%	-24.09%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-3.14%	12.77%	-26.70%
Free Cash Flow Firm Growth	-590.82%	33.05%	-57.10%
Invested Capital Growth	-12.04%	-16.71%	-18.50%
Revenue Q/Q Growth	3.07%	7.04%	1.16%
EBITDA Q/Q Growth	2.04%	4.08%	-13.50%
EBIT Q/Q Growth	1.85%	5.68%	-12.77%
NOPAT Q/Q Growth	-0.47%	7.97%	-15.58%
Net Income Q/Q Growth	-0.38%	2.71%	-9.96%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-1.96%	10.29%	-0.65%
Free Cash Flow Firm Q/Q Growth	3.30%	23.64%	2.28%
Invested Capital Q/Q Growth	-5.05%	-10.05%	-18.60%
Profitability Metrics	-	-	-
Gross Margin	88.11%	88.68%	90.18%
EBITDA Margin	-151.54%	-104.34%	-136.29%
Operating Margin	-122.82%	-79.23%	-107.06%
EBIT Margin	-156.32%	-105.29%	-132.96%
Profit (Net Income) Margin	-170.58%	-123.61%	-140.35%
Tax Burden Percent	101.62%	103.99%	102.28%
Interest Burden Percent	107.38%	112.90%	103.20%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	271.24%	132.29%	342.83%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-78.79%	-55.48%	-51.80%
Return on Assets (ROA)	-85.98%	-65.14%	-54.68%
Return on Common Equity (ROCE)	271.24%	132.29%	342.83%
Return on Equity Simple (ROE_SIMPLE)	122.85%	156.79%	1,441.26%
Net Operating Profit after Tax (NOPAT)	-55	-46	-68
NOPAT Margin	-85.97%	-55.46%	-74.94%
Net Nonoperating Expense Percent (NNEP)	-114.97%	-242.01%	-72.68%
Return On Investment Capital (ROIC_SIMPLE)	-	-134.20%	-59.12%
Cost of Revenue to Revenue	11.89%	11.32%	9.82%
SG&A Expenses to Revenue	128.72%	112.77%	134.02%
R&D to Revenue	82.21%	55.15%	63.21%
Operating Expenses to Revenue	210.92%	167.92%	197.24%
Earnings before Interest and Taxes (EBIT)	-101	-87	-120
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-98	-86	-123
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.18	5.60	4.97
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.13	5.08	3.65
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	-1.09	-1.52	-14.02
Long-Term Debt to Equity	-1.09	-1.52	-14.02
Financial Leverage	1.17	0.30	2.20
Leverage Ratio	-3.15	-2.03	-6.27
Compound Leverage Factor	-3.39	-2.29	-6.47
Debt to Total Capital	1,192.97%	290.77%	107.68%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	1,192.97%	290.77%	107.68%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	-1,092.97%	-190.77%	-7.68%
Debt to EBITDA	-1.00	-1.15	-1.00
Net Debt to EBITDA	0.04	0.50	0.97
Long-Term Debt to EBITDA	-1.00	-1.15	-1.00
Debt to NOPAT	-1.76	-2.17	-1.82
Net Debt to NOPAT	0.06	0.94	1.77
Long-Term Debt to NOPAT	-1.76	-2.17	-1.82
Altman Z-Score	-6.46	-4.41	-3.14
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	5.39	5.42	6.01
Quick Ratio	4.71	4.88	5.59
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-45	-30	-48
Operating Cash Flow to CapEx	-34,472.05%	-39,369.07%	-32,802.03%
Free Cash Flow to Firm to Interest Expense	-5.38	-2.06	-3.81
Operating Cash Flow to Interest Expense	-10.38	-5.19	-7.73
Operating Cash Flow Less CapEx to Interest Expense	-10.41	-5.20	-7.75
Efficiency Ratios	-	-	-
Asset Turnover	0.50	0.53	0.39
Accounts Receivable Turnover	5.27	5.88	5.06
Inventory Turnover	1.67	1.87	1.19
Fixed Asset Turnover	39.43	83.30	134.52
Accounts Payable Turnover	0.63	0.65	0.40
Days Sales Outstanding (DSO)	69.25	62.10	72.16
Days Inventory Outstanding (DIO)	218.34	194.92	306.19
Days Payable Outstanding (DPO)	583.81	563.84	903.54
Cash Conversion Cycle (CCC)	-296.23	-306.81	-525.19
Capital & Investment Metrics	-	-	-
Invested Capital	-93	-108	-128
Invested Capital Turnover	-0.73	-0.82	-0.76
Increase / (Decrease) in Invested Capital	-9.97	-16	-20
Enterprise Value (EV)	201	420	330
Market Capitalization	205	463	449
Book Value per Share	($3.87)	($2.11)	($0.21)
Tangible Book Value per Share	($3.87)	($2.11)	($0.21)
Total Capital	8.18	34	115
Total Debt	98	99	123
Total Long-Term Debt	98	99	123
Net Debt	-3.46	-43	-120
Capital Expenditures (CapEx)	0.25	0.19	0.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	4.21	0.19	-7.58
Debt-free Net Working Capital (DFNWC)	105	138	230
Net Working Capital (NWC)	105	138	230
Net Nonoperating Expense (NNE)	54	56	59
Net Nonoperating Obligations (NNO)	-3.46	-43	-120
Total Depreciation and Amortization (D&A)	3.07	0.78	-3.01
Debt-free, Cash-free Net Working Capital to Revenue	6.55%	0.22%	-8.38%
Debt-free Net Working Capital to Revenue	163.14%	166.81%	254.64%
Net Working Capital to Revenue	163.14%	166.81%	254.64%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($4.81)	($3.55)	($2.96)
Adjusted Weighted Average Basic Shares Outstanding	22.81M	28.83M	42.88M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	23.44M	34.12M	46.09M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	23.44M	34.12M	46.09M
Normalized Net Operating Profit after Tax (NOPAT)	-55	-46	-68
Normalized NOPAT Margin	-85.97%	-55.46%	-74.94%
Pre Tax Income Margin	-167.86%	-118.87%	-137.22%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-11.92	-5.92	-9.60
NOPAT to Interest Expense	-6.56	-3.12	-5.41
EBIT Less CapEx to Interest Expense	-11.95	-5.93	-9.62
NOPAT Less CapEx to Interest Expense	-6.59	-3.13	-5.43
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.15%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from UroGen Pharma's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	41.81%	11.86%	26.75%	27.31%	29.54%	30.06%	9.24%	3.35%	20.87%	4.40%
EBITDA Growth	25.61%	7.62%	0.78%	15.03%	17.04%	14.89%	-20.19%	-55.18%	-35.85%	-65.58%
EBIT Growth	24.32%	6.95%	1.85%	15.57%	17.14%	20.70%	-15.15%	-52.52%	-23.61%	-67.65%
NOPAT Growth	22.84%	-1.84%	-0.40%	17.81%	25.36%	27.97%	-16.76%	-67.98%	-29.96%	-89.32%
Net Income Growth	14.50%	-1.47%	-6.41%	9.57%	15.30%	9.88%	-6.86%	-38.39%	-8.20%	-44.19%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	4.68%	-8.38%	-7.55%	16.22%	1.78%	40.25%	-22.97%	-17.14%	-59.92%	-4.79%
Free Cash Flow Firm Growth	-107.83%	-107.05%	-106.96%	156.78%	114.05%	225.08%	-0.84%	-115.17%	-493.74%	-87.10%
Invested Capital Growth	-10.19%	-12.04%	-12.72%	-15.98%	-11.41%	-16.71%	-13.97%	-18.36%	-9.95%	-18.50%
Revenue Q/Q Growth	-3.05%	12.39%	-4.97%	22.96%	-1.36%	12.84%	-20.18%	16.33%	15.36%	-2.54%
EBITDA Q/Q Growth	7.44%	-11.71%	-8.70%	24.40%	9.63%	-14.60%	-60.41%	2.39%	20.89%	-39.69%
EBIT Q/Q Growth	6.69%	-10.73%	-7.51%	23.99%	8.43%	-5.98%	-56.11%	-0.68%	25.79%	-43.74%
NOPAT Q/Q Growth	3.36%	-12.14%	-8.69%	30.22%	12.24%	-8.21%	-76.19%	-0.38%	32.10%	-57.64%
Net Income Q/Q Growth	3.22%	-11.76%	-4.66%	20.11%	9.35%	-18.91%	-24.10%	-3.46%	29.13%	-58.46%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	27.22%	-23.51%	-18.64%	21.44%	14.67%	24.87%	-144.19%	25.17%	-16.49%	50.77%
Free Cash Flow Firm Q/Q Growth	-1.20%	5.96%	-11.98%	153.27%	-74.96%	737.19%	-177.84%	91.98%	-549.88%	127.43%
Invested Capital Q/Q Growth	-6.25%	-5.05%	-2.20%	-1.66%	-2.07%	-10.05%	0.97%	-5.58%	5.18%	-18.60%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.45%	87.49%	86.83%	88.44%	88.65%	90.28%	90.80%	89.80%	90.27%	89.94%
EBITDA Margin	-137.04%	-136.20%	-155.79%	-95.79%	-87.76%	-89.13%	-171.41%	-143.83%	-98.64%	-141.36%
Operating Margin	-112.36%	-112.10%	-128.23%	-72.77%	-64.74%	-62.09%	-137.05%	-118.27%	-69.61%	-112.59%
EBIT Margin	-142.30%	-140.19%	-158.61%	-98.05%	-91.02%	-85.48%	-167.19%	-144.69%	-93.08%	-137.27%
Profit (Net Income) Margin	-160.47%	-159.57%	-175.74%	-114.18%	-104.93%	-110.57%	-171.91%	-152.89%	-93.93%	-152.71%
Tax Burden Percent	102.82%	102.45%	100.07%	100.22%	99.96%	117.39%	100.17%	100.11%	100.39%	107.60%
Interest Burden Percent	109.67%	111.11%	110.72%	116.19%	115.33%	110.18%	102.65%	105.55%	100.52%	103.39%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	688.94%	271.24%	167.04%	121.61%	199.65%	132.29%	133.15%	210.11%	1,400.39%	342.83%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-67.55%	-70.66%	-77.39%	-58.88%	-43.67%	-45.05%	-89.91%	-65.22%	-33.57%	-53.49%
Return on Assets (ROA)	-76.17%	-80.43%	-85.75%	-68.57%	-50.34%	-58.26%	-92.45%	-68.91%	-33.87%	-59.50%
Return on Common Equity (ROCE)	688.94%	271.24%	167.04%	121.61%	199.65%	132.29%	133.15%	210.11%	1,400.39%	342.83%
Return on Equity Simple (ROE_SIMPLE)	172.81%	0.00%	95.75%	78.77%	250.27%	0.00%	259.92%	-374.69%	-452.20%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	-14	-15	-11	-9.45	-10	-18	-18	-12	-19
NOPAT Margin	-78.65%	-78.47%	-89.76%	-50.94%	-45.32%	-43.46%	-95.94%	-82.79%	-48.73%	-78.81%
Net Nonoperating Expense Percent (NNEP)	-19.25%	-30.98%	-65.10%	-10,127.73%	-30.49%	-67.79%	-61.63%	-29.89%	-11.98%	-22.31%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-29.92%	-	-	-	-16.90%
Cost of Revenue to Revenue	12.55%	12.51%	13.17%	11.56%	11.35%	9.72%	9.20%	10.20%	9.73%	10.06%
SG&A Expenses to Revenue	118.48%	119.58%	142.36%	106.41%	104.33%	104.34%	145.35%	137.57%	114.83%	141.90%
R&D to Revenue	81.34%	80.02%	72.70%	54.80%	49.06%	48.03%	82.50%	70.50%	45.05%	60.63%
Operating Expenses to Revenue	199.81%	199.60%	215.05%	161.21%	153.39%	152.37%	227.85%	208.06%	159.88%	202.53%
Earnings before Interest and Taxes (EBIT)	-23	-25	-27	-21	-19	-20	-31	-32	-23	-34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	-25	-27	-20	-18	-21	-32	-31	-25	-35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.00	20.96	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.00	20.96	0.00
Price to Revenue (P/Rev)	3.03	3.18	3.19	3.35	5.49	5.60	6.07	7.13	5.99	4.97
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.63	3.13	3.50	3.93	4.76	5.08	5.27	5.43	4.49	3.65
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-1.14	-1.09	-0.84	-0.71	-2.35	-1.52	-2.43	3.23	4.77	-14.02
Long-Term Debt to Equity	-1.14	-1.09	-0.84	-0.71	-2.35	-1.52	-2.43	3.23	4.77	-14.02
Financial Leverage	4.31	1.17	0.34	0.00	0.77	0.30	0.30	0.95	11.54	2.20
Leverage Ratio	-8.29	-3.15	-2.09	-1.35	-3.06	-2.03	-2.00	-3.49	-30.08	-6.27
Compound Leverage Factor	-9.09	-3.51	-2.31	-1.56	-3.53	-2.24	-2.05	-3.68	-30.23	-6.48
Debt to Total Capital	837.26%	1,192.97%	-526.20%	-244.90%	174.29%	290.77%	169.85%	76.34%	82.67%	107.68%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	837.26%	1,192.97%	-526.20%	-244.90%	174.29%	290.77%	169.85%	76.34%	82.67%	107.68%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-737.26%	-1,092.97%	626.20%	344.90%	-74.29%	-190.77%	-69.85%	23.66%	17.33%	-7.68%
Debt to EBITDA	-0.72	-1.00	-1.01	-1.05	-1.09	-1.15	-1.07	-0.96	-1.12	-1.00
Net Debt to EBITDA	0.25	0.04	-0.22	-0.45	0.63	0.50	0.75	1.42	1.23	0.97
Long-Term Debt to EBITDA	-0.72	-1.00	-1.01	-1.05	-1.09	-1.15	-1.07	-0.96	-1.12	-1.00
Debt to NOPAT	-1.31	-1.76	-1.77	-1.85	-1.98	-2.17	-2.01	-1.75	-2.08	-1.82
Net Debt to NOPAT	0.46	0.06	-0.39	-0.79	1.13	0.94	1.40	2.59	2.28	1.77
Long-Term Debt to NOPAT	-1.31	-1.76	-1.77	-1.85	-1.98	-2.17	-2.01	-1.75	-2.08	-1.82
Altman Z-Score	-4.53	-4.62	-6.40	-7.92	-2.60	-3.17	-2.77	-1.28	-1.32	-2.14
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.40	5.39	3.80	3.04	7.06	5.42	7.47	8.15	9.00	6.01
Quick Ratio	5.54	4.71	3.07	2.35	6.21	4.88	6.77	7.55	8.31	5.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4.49	-4.22	-4.73	2.52	0.63	5.28	-4.77	-0.38	-2.48	0.68
Operating Cash Flow to CapEx	-11,511.11%	-167,323.08%	-112,204.35%	-135,160.00%	-17,299.00%	-23,207.14%	0.00%	-28,271.43%	-28,816.67%	-11,842.61%
Free Cash Flow to Firm to Interest Expense	-1.67	-1.31	-1.33	0.67	0.17	1.47	-1.95	-0.11	-0.91	0.18
Operating Cash Flow to Interest Expense	-6.54	-6.75	-7.26	-5.39	-4.53	-3.62	-12.97	-6.86	-10.17	-3.50
Operating Cash Flow Less CapEx to Interest Expense	-6.59	-6.75	-7.27	-5.39	-4.56	-3.64	-12.97	-6.89	-10.20	-3.53
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.50	0.49	0.60	0.48	0.53	0.54	0.45	0.36	0.39
Accounts Receivable Turnover	7.25	5.27	6.18	5.35	6.94	5.88	6.33	5.16	5.01	5.06
Inventory Turnover	1.61	1.67	1.64	1.79	1.89	1.87	1.39	1.39	1.38	1.19
Fixed Asset Turnover	35.71	39.43	47.21	57.67	65.99	83.30	101.02	114.11	124.90	134.52
Accounts Payable Turnover	0.68	0.63	0.62	0.72	0.80	0.65	0.50	0.43	0.52	0.40
Days Sales Outstanding (DSO)	50.31	69.25	59.04	68.20	52.61	62.10	57.70	70.67	72.80	72.16
Days Inventory Outstanding (DIO)	226.69	218.34	222.24	203.69	192.78	194.92	262.85	263.47	264.35	306.19
Days Payable Outstanding (DPO)	533.85	583.81	588.46	508.47	458.09	563.84	729.83	851.18	708.68	903.54
Cash Conversion Cycle (CCC)	-256.85	-296.23	-307.18	-236.58	-212.70	-306.81	-409.29	-517.04	-371.53	-525.19
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-88	-93	-95	-96	-98	-108	-108	-114	-108	-128
Invested Capital Turnover	-0.74	-0.73	-0.76	-0.81	-0.83	-0.82	-0.83	-0.81	-0.86	-0.76
Increase / (Decrease) in Invested Capital	-8.17	-9.97	-11	-13	-10	-16	-13	-18	-9.80	-20
Enterprise Value (EV)	164	201	238	285	368	420	444	462	401	330
Market Capitalization	189	205	217	243	424	463	512	606	535	449
Book Value per Share	($2.78)	($3.87)	($4.97)	($5.90)	($1.39)	($2.11)	($1.18)	$0.84	$0.61	($0.21)
Tangible Book Value per Share	($2.78)	($3.87)	($4.97)	($5.90)	($1.39)	($2.11)	($1.18)	$0.84	$0.61	($0.21)
Total Capital	8.58	8.18	-19	-40	57	34	57	128	147	115
Total Debt	72	98	98	98	99	99	98	98	122	123
Total Long-Term Debt	72	98	98	98	99	99	98	98	122	123
Net Debt	-25	-3.46	22	42	-56	-43	-68	-144	-134	-120
Capital Expenditures (CapEx)	0.15	0.01	0.02	0.02	0.10	0.06	0.00	0.08	0.10	0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	5.87	4.21	4.87	6.45	8.10	0.19	5.55	2.84	12	-7.58
Debt-free Net Working Capital (DFNWC)	103	105	71	55	156	138	170	245	262	230
Net Working Capital (NWC)	103	105	71	55	156	138	170	245	262	230
Net Nonoperating Expense (NNE)	13	15	15	13	12	16	14	15	11	18
Net Nonoperating Obligations (NNO)	-25	-3.46	22	42	-56	-43	-68	-144	-134	-120
Total Depreciation and Amortization (D&A)	0.85	0.72	0.49	0.48	0.68	-0.86	-0.79	0.19	-1.40	-1.01
Debt-free, Cash-free Net Working Capital to Revenue	9.40%	6.55%	7.16%	8.90%	10.48%	0.22%	6.59%	3.34%	13.05%	-8.38%
Debt-free Net Working Capital to Revenue	164.31%	163.14%	104.05%	75.25%	202.31%	166.81%	202.15%	287.90%	293.53%	254.64%
Net Working Capital to Revenue	164.31%	163.14%	104.05%	75.25%	202.31%	166.81%	202.15%	287.90%	293.53%	254.64%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.13)	($1.25)	($1.30)	($1.03)	($0.68)	($0.54)	($0.97)	($0.91)	($0.55)	($0.53)
Adjusted Weighted Average Basic Shares Outstanding	22.80M	22.81M	23.28M	23.46M	32.30M	28.83M	33.38M	36.82M	43.10M	42.88M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	23.09M	23.44M	23.45M	30.28M	30.87M	34.12M	36.13M	42.11M	42.20M	46.09M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	23.09M	23.44M	23.45M	30.28M	30.87M	34.12M	36.13M	42.11M	42.20M	46.09M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-14	-15	-11	-9.45	-10	-18	-18	-12	-19
Normalized NOPAT Margin	-78.65%	-78.47%	-89.76%	-50.94%	-45.32%	-43.46%	-95.94%	-82.79%	-48.73%	-78.81%
Pre Tax Income Margin	-156.07%	-155.76%	-175.62%	-113.92%	-104.97%	-94.19%	-171.62%	-152.71%	-93.56%	-141.92%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.50	-7.87	-7.67	-5.51	-4.97	-5.61	-12.83	-9.13	-8.62	-8.66
NOPAT to Interest Expense	-4.70	-4.41	-4.34	-2.86	-2.48	-2.85	-7.36	-5.23	-4.51	-4.97
EBIT Less CapEx to Interest Expense	-8.56	-7.87	-7.68	-5.51	-5.00	-5.62	-12.83	-9.16	-8.66	-8.69
NOPAT Less CapEx to Interest Expense	-4.76	-4.41	-4.35	-2.87	-2.50	-2.87	-7.36	-5.25	-4.55	-5.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.16%	-0.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About UroGen Pharma's Financials

When does UroGen Pharma's financial year end?

According to the most recent income statement we have on file, UroGen Pharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has UroGen Pharma's net income changed over the last 2 years?

UroGen Pharma's net income appears to be on an upward trend, with a most recent value of -$126.87 million in 2024, rising from -$109.78 million in 2022. The previous period was -$102.24 million in 2023.

What is UroGen Pharma's operating income?

UroGen Pharma's total operating income in 2024 was -$96.78 million, based on the following breakdown:

Total Gross Profit: $81.52 million
Total Operating Expenses: $178.30 million

How has UroGen Pharma revenue changed over the last 2 years?

Over the last 2 years, UroGen Pharma's total revenue changed from $64.36 million in 2022 to $90.40 million in 2024, a change of 40.5%.

How much debt does UroGen Pharma have?

UroGen Pharma's total liabilities were at $294.51 million at the end of 2024, a 20.9% increase from 2023, and a 30.9% increase since 2022.

How much cash does UroGen Pharma have?

In the past 2 years, UroGen Pharma's cash and equivalents has ranged from $55.41 million in 2022 to $171.99 million in 2024, and is currently $171.99 million as of their latest financial filing in 2024.

How has UroGen Pharma's book value per share changed over the last 2 years?

Over the last 2 years, UroGen Pharma's book value per share changed from -3.87 in 2022 to -0.21 in 2024, a change of -94.6%.

Remove Ads

Related Companies

This page (NASDAQ:URGN) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

UroGen Pharma (URGN) Financials

Frequently Asked Questions About UroGen Pharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

UroGen Pharma (URGN) Financials

Annual Income Statements for UroGen Pharma

Quarterly Income Statements for UroGen Pharma

Annual Cash Flow Statements for UroGen Pharma

Quarterly Cash Flow Statements for UroGen Pharma

Annual Balance Sheets for UroGen Pharma

Quarterly Balance Sheets for UroGen Pharma

Annual Metrics and Ratios for UroGen Pharma

Quarterly Metrics and Ratios for UroGen Pharma

Frequently Asked Questions About UroGen Pharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools